Business Wire

Scientist.com Announces Launch of Research Marketplace for BIAL

Share

Scientist.com, the biopharma industry’s leading R&D platform, today announced the launch of a private online marketplace for BIAL. The partnership will connect BIAL researchers with over 4,000 pre-signed service providers available on Scientist.com’s digital platform.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230111005035/en/

"As a leading Neuroscience R&D pharmaceutical company, we understand the importance of having reliable access to information, efficient processes and the right resources. That is why we are excited to partner with Scientist.com to streamline our R&D efforts and connect with the best scientific research partners and solution providers,” said Joerg Holenz, General Manager of BIAL R&D. “With this partnership, we can better focus on what matters most: delivering innovative solutions to cure diseases."

BIAL is an R&D focused pharmaceutical company that is headquartered in Portugal and has operations in various locations around the world, notably in the most competitive European pharmaceutical markets. The company is committed to discovering, developing and bringing to market innovative medicines. BIAL's main focus is on two therapeutic areas: Parkinson's Disease, which affects more than 10 million people globally, and epilepsy, which impacts over 50 million people worldwide.

"At Scientist.com, we are committed to supporting companies like BIAL that are dedicated to improving the lives of people living with neurological diseases. BIAL's innovative medications are making a real impact on a global scale, and we are proud to partner with them and support their commitment to discovering and developing new treatments in the neurosciences. Together, we can make a difference in the lives of those who need it most,” said Kevin Lustig, PhD, CEO and Founder of Scientist.com.

Scientist.com currently operates award-winning research marketplaces for 24 of the world’s top 30 pharmaceutical companies, over 100 biotech companies and the National Institutes of Health (NIH). The company’s Science as a Service® platform digitizes a company’s entire research operations, enabling researchers to focus more of their time on experimental design and results analysis. Scientist.com helps researchers outsource everything but the genius.

About BIAL

BIAL is an innovation-driven pharmaceutical company aiming to improve people’s lives worldwide. With 98 years of experience, BIAL is strongly committed to therapeutic innovation, consistently investing over 20% of its annual turnover in R&D, being neurosciences its major area of research. Based on its own innovative medicines and with a consistent partnering program, BIAL has extended its presence worldwide. The company has ten affiliates in three different continents – Europe, America and Africa – and its products are present in fifty countries, fulfilling its purpose of making a real difference in the lives of people all over the world.

For more information about BIAL, please visit www.bial.com.

About Scientist.com

Scientist.com's mission is to empower and connect scientists worldwide. The company's digital research platform combines a custom-built, cloud native technology stack with white-glove customer and scientific support to enable scientists to run more innovative experiments in less time and at lower cost. Scientist.com leverages internally developed machine learning models to provide actionable insights that improve operational efficiency and effective research management. Scientist.com connects the world's top pharmaceutical companies, biotechnology companies and the US National Institutes of Health (NIH) to the world's largest network of scientific suppliers.

Join Scientist.com on social media: YouTube, LinkedIn, Twitter, Facebook and Instagram.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Sean Preci
marketing@scientist.com
+1 858-815-9274

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Smiths Detection deploys multi-site central image processing solution for DHL Express Australia31.1.2023 00:00:00 CET | Press release

Smiths Detection, a global leader in threat detection and security screening technologies, today announces that it has deployed a fully operational multi-site central image processing and management solution for DHL Express Australia. The solution connects existing Smiths Detection HI-SCAN 10080 EDX-2is high-speed automatic explosive detection scanners at the sites in Sydney, Melbourne and Brisbane into one intelligent network that allows all X-ray images to be analysed at a single central location and provides consolidated data analytics and insights. The intelligent centralised screening solution will enable DHL Express Australia to optimise staffing rostering, as well as significantly increase the utilisation of its security operators while reducing overall operational expenditure. The technology will be used for the safe and efficient screening of international air freight, in line with both TSA and Australian regulations. Ajay Sankaran, Managing Director of Australia & Sales Direc

Valbiotis Announces Positive Results in the Bioavailability and Mode of Action TOTUM•854 Clinical Study, Against High Blood Pressure30.1.2023 17:40:00 CET | Press release

Regulatory News: Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible) (Paris:ALVAL), a commercially oriented Research and Development company, with a commercial purpose, committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces positive results in the bioavailability and mode of action clinical study conducted on TOTUM•854 against high blood pressure, the number one cardiovascular risk factor worldwide. The mode of action results demonstrate a protective effect of TOTUM•854 on vascular wall cells and a reduction in angiotensin I-converting enzyme (ACE1) activity in humans. These robust data confirm the potential of TOTUM•854 to reduce blood pressure at the earliest stages of arterial hypertension, which affect 123 million people in the US and Europe1. They hold great promise for the late-stage clinical development of TOTUM•854. Pascal SIRVENT, Director of Discovery and Preclinical and Translational Research, member of the Executive

Boomi Named a Leader for Ninth Consecutive Time in Gartner® Magic Quadrant™ for Integration Platform as a Service, Worldwide30.1.2023 17:28:00 CET | Press release

BoomiTM, the intelligent connectivity and automation leader, today announced that Gartner has positioned Boomi as a Leader in its Magic Quadrant for Integration Platform as a Service (iPaaS), Worldwide for the ninth consecutive time. Gartner evaluated 16 iPaaS providers on their ability to execute and completeness of vision. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230130005154/en/ Boomi Named a Leader for Ninth Consecutive Time in Gartner® Magic Quadrant™ for Integration Platform as a Service, Worldwide (Graphic: Business Wire) The iPaaS market is projected to reach $11 billion in revenue by 2026.1 Given the advanced capabilities and immense scale of iPaaS vendors, [iPaaS] has become the strategic integration platform of choice for hundreds of thousands of organizations around the world. In many cases, iPaaS has replaced previous generations of integration platform software such as application integration suites, data

Aspen Appoints Mike Duffy To U.K. Boards30.1.2023 16:16:00 CET | Press release

Aspen Insurance Holdings Limited (“Aspen”) is pleased to announce that Mike Duffy has been appointed to the Aspen Managing Agency Limited (“AMAL”) and Aspen Insurance UK Limited (“AIUK”) Boards as a Non-Executive Director, effective February 1, 2023. Mike will join the AMAL and AIUK (together, “Aspen U.K.”) Boards as Senior Independent Non-Executive Director (“SID”), Chair of the Nominations Committee, and Chair of the Governance Committee, subject to regulatory approval. Mike is a vastly experienced and highly respected leader in the Lloyd’s market with a 40-year career across underwriting and broking. He was most recently Group Chief Underwriting Officer for Canopius, where he held several Board roles across the Canopius corporate group of entities. In addition, he has held numerous leadership positions across a range of broking and insurance groups. During his extensive career, Mike has gained significant risk, governance, transaction and regulatory experience across the U.K., U.S.,

Planview Continues Acceleration with Record Revenue in FY’2230.1.2023 15:00:00 CET | Press release

Planview, the leading platform for connected work from portfolio planning to delivery, today announced record annual recurring revenue (ARR) for fiscal year 2022, continuing a trend of strong performance. Planview exceeded $380 million in total ARR for 2022, representing 17% growth year-over-year (YoY). “It was another record year for Planview, underpinned by our commitment to build the digital future of connected work through product innovation and customer success,” said Razat Gaurav, Chief Executive Officer, Planview. “The macroeconomic uncertainties and headwinds faced by organizations today make prioritizing product and project initiatives, and thoughtfully allocating constrained resources and capital, more important than ever. Our global customer base relies on our solutions to help them achieve productivity, efficiency, and positive business outcomes from transformation initiatives across the enterprise.” Fiscal Year-End Highlights Planview achieved record levels for the full fi